Although additional evidence is needed to confirm whether the inhibition of Akt signaling in our experiments impacted TME matrix stiffness, our data on tumor histology and major stromal component gene expression did not support a clear involvement of TME matrix alternation in the observed therapeutic benefits derived from Akt signaling inhibition. The gene discussed is AKT1; the disease is neoplasm.